Abstract
Objective Current evidences support that squamous cell carcinomas (SCCs) of the oral cavity (OSCC) and oropharynx (OPSCC) are distinct and unique, with differences on its pathogenesis, treatment, and prognosis. SMARCB1/INI1 is a potent tumor suppressor, whereas nuclear protein in testis (NUT) antibody identifies midline carcinoma (NMC), a rare aggressive carcinoma typically located on the midline of the head and neck. Although with different clinicopathological features, OPSCC and NMC share anatomic location. Interestingly, the SMARCB1/INI1 and NUT expression profile in OSCC and OPSCC is unknown. Study Design The immunohistochemical analysis of SMARCB1/INI1 and NUT antibodies were performed on tissue microarrays containing 108 OSCC and 52 OPSCC formalin-fixed paraffin-embedded samples. Results Only 3 cases (2 OSCC and 1 OPSCC) were SMARCB1/INI1 negative, whereas 3 cases (2 OPSCC and 1 OSCC) were NUT positive. Moreover, SMARCB1/INI positivity was observed in surface epithelium, endothelial cells, mononuclear inflammatory cells, salivary gland ducts and sebaceous gland acini, whereas 7 cases with only intense cytoplasmic staining for NUT were considered nonspecific. Conclusions Our results show that SMARCB1/INI1+/NUT- immunoexpression profile is prevalent when assessing OSCC and OPSCC. However, it is recommended to analyze these antibodies, because of the prognostic effect of identifying SMARCB1/INI1-deficient SCC and NMC cases. FAPESP (2016/11419-0). Current evidences support that squamous cell carcinomas (SCCs) of the oral cavity (OSCC) and oropharynx (OPSCC) are distinct and unique, with differences on its pathogenesis, treatment, and prognosis. SMARCB1/INI1 is a potent tumor suppressor, whereas nuclear protein in testis (NUT) antibody identifies midline carcinoma (NMC), a rare aggressive carcinoma typically located on the midline of the head and neck. Although with different clinicopathological features, OPSCC and NMC share anatomic location. Interestingly, the SMARCB1/INI1 and NUT expression profile in OSCC and OPSCC is unknown. The immunohistochemical analysis of SMARCB1/INI1 and NUT antibodies were performed on tissue microarrays containing 108 OSCC and 52 OPSCC formalin-fixed paraffin-embedded samples. Only 3 cases (2 OSCC and 1 OPSCC) were SMARCB1/INI1 negative, whereas 3 cases (2 OPSCC and 1 OSCC) were NUT positive. Moreover, SMARCB1/INI positivity was observed in surface epithelium, endothelial cells, mononuclear inflammatory cells, salivary gland ducts and sebaceous gland acini, whereas 7 cases with only intense cytoplasmic staining for NUT were considered nonspecific. Our results show that SMARCB1/INI1+/NUT- immunoexpression profile is prevalent when assessing OSCC and OPSCC. However, it is recommended to analyze these antibodies, because of the prognostic effect of identifying SMARCB1/INI1-deficient SCC and NMC cases. FAPESP (2016/11419-0).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
